Gilead Sciences – Recall of Veklury® (remdesivir)

- On December 3, 2021, Gilead Sciences announced a voluntary, consumer-level recall of two lots of Veklury (remdesivir) 100 mg injection due to the presence of glass particulates.
    - Clinical Services through the Drug Safety Notification program will not message members and providers regarding the recall because no utilizing members were identified.
    - Other Veklury injection vials that are not being recalled are available for patients to use.
- The Veklury lyophilized 100 mg injection vials were distributed nationwide from October 25, 2021 to November 2, 2021.

Product Description	NDC	Lot # (Expiration Date)
Veklury (remdesivir) 100 mg for injection	61958-2901-02	2141001-1A (1/2024); 2141002-1A (1/2024)

- Veklury is indicated for the treatment of adults and pediatric patients ≥ 12 years old and weighing ≥ 40 kg requiring hospitalization for COVID-19.
- The administration of an injectable product that contains glass particulates may result in local irritation or swelling in response to the foreign material. If the glass particulate reaches the blood vessels it can travel to various organs and block blood vessels in the heart, lungs or brain which can cause stroke and even lead to death.
- To date, Gilead Sciences has not received any reports of adverse events related to this recall.
- Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to the recalled Veklury injection.
- Anyone with an existing inventory of the recalled product should stop use, distribution and quarantine the product immediately.
- Contact Gilead Medical Information by phone at **1-866-633-4474** or through their website at **www.askgileadmedical.com** for more information about the recall.